Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 3Active not recruiting 2Withdrawn 1Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 15Meningeal Carcinomatosis 3Respiratory Tract Neoplasms 1Non Small Cell Lung Cancer NSCLC 1NSCLC 1Lung Neoplasms 1Bronchial Neoplasms 1Advanced Non-small Cell Lung Cancer 1Advanced Lung Cancer 1Adenocarcinoma of Lung 1

Interventions

Drug Therapy 4Pemetrexed 3Carboplatin 3osimertinib 2Radiotherapy 2toripalimab 1tislelizumab 1sugemalimab 1spartalizumab 1sintilimab 1pembrolizumab 1cemiplimab 1aflutinib 1Vinorelbine 1Radiosurgery 1Platinum 1Paclitaxel 1Gemcitabine 1Docetaxel 1Cisplatin 1Chemotherapy, Adjuvant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × NSCLC × aflutinib × Clear all
NCT05994131 2025-04-30

IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC

InxMed (Shanghai) Co., Ltd.

Phase 1/2 Recruiting
110 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡